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DELAYED INFUSION OF ALLOANERGIZED DONOR PERIPHERAL BLOOD
MONONUCLEAR CELLS (PBMC) AUGMENTS PATHOGEN-SPECIFIC IM-
MUNE RECONSTITUTION AFTER T CELL DEPLETED (TCD) HAPLOIDENT-
ICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR
HIGH-RISK ACUTE LEUKEMIA/MDS
Davies, J.K.1, De Lima, M.4, Cooper, L.J.N.5, Spitzer, T.2, Kapoor, N.3,
Yuk, D.1, Brennan, L.L.1, Thall, P.4, McMannis, J.4, Champlin, R.4,
Nadler, L.M.1, Guinan, E.C.1 1 Dana-Farber Cancer Institute, Boston,
MA; 2 Massachusetts General Hospital, Boston, MA; 3 Children’s Hospital
Los Angeles, Los Angeles, CA; 4 M.D. Anderson Cancer Center, Houston,
TX; 5 Children’s Cancer Hospital, M.D. Anderson Cancer Center, Hous-
ton, TX
Adoptive transfer of alloanergized donor T cells is a simple ap-
proach to augment immune reconstitution while limiting GvHD af-
ter TCD haploidentical (haplo) HSCT. However the optimal dose
and impact on antigen-specific immune reconstitution remain un-
known. On a new study, 7 adults and 4 children received fractionated
TBI (12Gy, n 5 5) or melphalan (140mg/m2, n 5 6), fludarabine,
thiotepa and ATG followed by CD34-selected peripheral blood
stem cells (median 9.4 CD341 and 0.02 CD31 106 cells/kg) from
haplo donors without further GvHD prophylaxis. All engrafted rap-
idly with full donor chimerism. Using an adaptive trial design, 10 pts
received alloanergized donor PBMC (generated by co-culture with
irradiated stimulator PBMC and humanized anti-B7.1 and -B7.2 an-
tibodies resulting in a median 6-fold reduction in alloresponses) in
escalating dose (Ds) cohorts: Ds1, 103 CD31 cells/kg (n 5 4), Ds2
104/kg (n5 3) and Ds3 105/kg (n5 3). 3 pts developed Gr 2–4 acute
GvHD, (1 Ds 2, 2 Ds3), all responding to treatment. 0/7 evaluable
pts developed chronic GvHD. 7/11 pts are alive (median f/u 8
months). 3 pts died from regimen related toxicity before D1100
and 1 from post-operative bleeding (D1738). 2 pts relapsed. CD4
T cell recovery was faster and functional pathogen-specific CD4
and CD8 T cells became detectable earlier in pts receiving higher
doses of alloanergized PBMC. Median time to CD4 ct .100/ml
was 9, 3 and 2 months and CMV or VZV-specific IFN-g1 T cells
became detectable at 7.5, 3 and 2.5 months at Ds 1,2 and 3 respec-
tively. The effector memory phenotype of recovering T cells was
consistent with peripheral expansion of infused alloanergized donor
T cells. 5 pts reactivated CMV before alloanergized PBMC infusion,
but no new episodes of CMV reactivation or CMV disease occurred
after infusion. 2 pts had large expansions of CMV-specific CD4 and
CD8 T cells (up to 10%) before D1100, coinciding with clearance
of CMV viremia. One Ds3 pt had adenoviremia despite high dose ci-
dofovir, resolving with expansion of infused donor T cells. 2 Ds1 pts
developed late viral infections: 1 reactivated EBV, and 1 developed
disseminated VZV resolving after VZV-specific T cells became de-
tectable. No late viral infections occurred in assessable Ds2/3 pts.
These early data support a contribution of alloanergized donor
PBMC to quantitative and qualitative immune reconstitution after
TCD haploHSCT. Further recruitment will determine the optimal
dose that can be safely administered in this setting.388
RAPID LYMPHOCYTE RECOVERY AND INTRAVENOUS IMMUNOGLOBU-
LIN INDEPENDENCE IN CHILDREN WITH SEVERE COMBINED IMMUNO-
DEFICIENCY (SCID) UNDERGOING ALLOGENEIC STEM CELL
TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING (RIC)
Guarino, J.A., Kletzel, M., Schneiderman, J., Jacobsohn, D.,
Chaudhury, S., Duerst, R., Tse, W. Children’s Memorial Hospital, North-
western University Feinberg School of Medicine, Chicago, IL
Allogeneic SCT is curative for patients with SCID. We evaluated
aRICSCTapproach in thesepatients for engraftment, toxicityand im-
mune reconstitution. Between 2000 and 2008,RIC transplantwas per-
formed in 14 SCID patients (8 males and 6 females; median age 5
months (range 1.1–98.3)). Median time from diagnosis to transplant
was 1.8 months (range 1.0–96.3). Donor sources included: HLA-
matched related donor peripheral blood stemcells (PBSC) (n5 1), un-
related donor PBSC (7), related cord blood (CB) (1) and unrelated CB
(6). The median cell dose was 10.3  108 TNC/kg and 9.2  106
CD341cells/kg, and 2.0  108 TNC/kg and 1.5  106
CD341cells/kg for the PBSC and CB groups, respectively. RIC regi-
men includedFludarabine 30mg/m2/day, days -10 through -5, intrave-nous Busulfan targeted to AUC 4000–5000 microMol*min/day, days
-5 and -4, and anti-thymocyte globulin 2mg/kg/day, days -4 through
-1. GVHD prophylaxis included cyclosporine A and mycophenolate
mofetil. Engraftment occurred in 8/8 (100%) PBSC recipients and
4/6 (67%) CB recipients. Absolute neutrophil count (ANC) .1000
was achieved at a median of 17 days (range 4–26) and platelets.50K
was achieved at amedian of 23 days (12–90). The ANCnever dropped
\500 for 8/14 (57%), and platelets never dropped\20K for 8/14
(57%) patients. Full donor chimerism (VNTR$ 95%) was achieved
by a median of 26 days in 11/14 patients (79%; 8 received PBSC, 3 re-
ceived CB). Stable mixed donor chimerism (VNTR $ 50%) was
achieved by 74 days for 1 patient who received CB. Two patients
who received CB doses of 1.19/1.99  108 TNC/kg, and 0.69/0.55
 106 CD341cells/kg, respectively, experienced graft failure and
died from complications. The other patients tolerated the transplant
with mild toxicities. No VOD or grade III/IV acute or chronic
GVHD was seen. Infections seen post-transplant (bacterial (n 5 9),
candidemia (1), and viral (8)) responded to antimicrobial therapy ex-
cept in 1 graft failure patient. Immune reconstitution studies per-
formed post-transplant showed rapid recovery of various lymphocyte
subsets (table). Normal endogenous IgG levels were achieved by day
1180 and patients no longer required IV immunoglobulin. The
100-day transplant mortality was 14.3%. The Kaplan-Meier estimate
of overall survival at 2 years was 80% (95% CI 47.5–90%). This RIC
SCT protocol is a novel, non-toxic approach that allows for adequate
donor engraftmentwithearly immune reconstitution andcorrectionof
the underlying immunodeficiency in children with SCID.
Immune Reconstitution Post-RIC SCT *
Pre-SCT Day 1100 Day 1180 Day 1270 Day 1365(n514) (n511) (n511) (n511) (n57) p value**Absolute
Lymphocyte
Count
(NL.2500)2302 6 654 2645 6 630 3902 6 573 5628 6 1003 6978 6 788 0.0005CD41
(NL.1000)
499 6 379 415 6 95 806 6 181 1813 6 283 2523 6 441 0.0001CD81
(NL.800)
81 6 51 597 6 182 961 6 300 1571 6 515 1652 6 290 0.0001CD191
(NL.600)
1494 6 461 985 6 320 1078 6 218 1272 6 249 1543 6 218 0.55CD161CD561
(NL.200)
249 6 110 535 6 142 901 6 190 842 6 204 911 6 165 0.002Endogenous IgG
(NL$500)
415 6 95 N/A*** 933 6 198 828 6 223 654 6 175 0.03*All values are reported as mean 6 SEM. Cell counts are expressed in
cells/mm3 and IgG in mg/dl. NL5normal value.
**Statistical significance of differences by non-parametric ANOVA using
the Kruskal-Wallis test.
***Patients received IV immunoglobulin during the first 100 days post-
transplant.389
NK CELL RECONSTITUTION AFTER ALLOGENEIC TRANSPLANTATION
FROM UNRELATED DONORS USING CD3/CD19 DEPLETED GRAFT
Diaz, M.A., Gonzalez Vicent, M., Perez, A., Sevilla, J., Abad, L.,
Ramirez, M. Hospital Nin˜o Jesus, Madrid, Spain
We analyzed immune recovery after allogeneic PBSC transplanta-
tion from unrelated donors using CD3/CD19 depleted graft. Between
June 2005 and June 2008, thirteen pediatric patients (9 males and 4 fe-
males) aged between 1 and 16 years (median 5 years) diagnosed of leu-
kemiawere included.Tenpatientswere in1stCRand three in2ndCR.A
fludarabine-RICwasused.GraftsweremanipulatedbyCD3/CD19de-
pletion usingCliniMACSCell Separation System.Graft composition
was as follows: CD341; 11.0 106/kg (range; 5.66- 62.77),CD31; 0.5
 105/kg (range; 0.1–2.07) and CD561; 44.45  106/kg (range; 17.0–
149.82).Resultswere compared to a groupof pediatric patients (n5 13)
with leukemia conditioned with the same RIC and grafted with
aCD341 selectedPBSCfromunrelateddonors.Therewerenotdiffer-
ences inT andB lymphocyte recovery between groups.However, a sig-
nificantly difference was observed in the NK cell reconstitution. NK
140 Poster Session-IIcells peakaroundday130.MediannumberofNKcells onday130was
420/ml (range; 161–1167) in CD3/CD19 depleted group compared to
234/ml (range; 9- 644) in theCD341 selected group.On day1100 the
median number of NK cells/ml were 210 (range; 25–350) versus 68
(range; 50–123) (p 5 0.02) respectively. Recipient NK cell phenotype
and function were analyzed and compared to donor NK cells. We ob-
servedanincreaseofCD56brightNKcell subset inbothgroups.Theme-
dianpercentage ofCD56bright cells amongNKcells in peripheral blood
was 21.4% (range; 7.8–46%) for patients receiving a CD3/CD19 de-
pleted graft and 33% (range; 17.7–62%) (p\0.05). On day 1100 the
median percentage of CD56bright cells were 13.4% (range; 4.6–22%)
and 37.5% (range; 22.5–61%) (p 5 0.001) respectively. Patients NK
cell cytotoxicity was lower at time of engraftment (3%) compared to
their respective donors (20%) (p\0.05) and reached the donor values
by day1100.Weobserved a diminishedKIR expression onKIR2DL1,
KIR2DL2 and especially in KIR3DL1. We also observed a lower ex-
pression of activating receptors NKp30 and NKp44 and in the activat-
ing C-type lectin receptor NKG2D. The expression of CD69 was also
lower comparedwith their respective donors.These results suggest that
NKrepertoire early after unrelated transplantation isdeterminedby the
imbalance between CD56bright and NK CD56dim subsets. This imbal-
ance is higher in patients undergoing unrelated transplantation using
CD341 selected graft compared to those patients receiving a CD3/
CD19 depleted graft.
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IMMUNE RECONSTITUTION OF REGULATORY T-CELLS FOLLOWING AU-
TOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
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The regulatory function of CD41CD25highCD127dim T-cells
(Tregs) has been associated with the risk of disease relapse, with
GVHD in the allogeneic HSCT setting, and with the immunomod-
ulatory capacity of autologous HSCT for autoimmune disorders.
Despite their potentially important role in HSCT, their patterns
of immune reconstitution postransplant remain unknown. In this
study, we have analyzed the kynetics of immune reconstitution of
Tregs in 42 adult (median age 56, 28–74), 27 male and 15 female, re-
cipients of an autologous peripheral blood HSCT following condi-
tioning with Melphalan-200 (multiple myeloma, n 5 31) or BEAM
(NHL, n 5 11) from May 2006 to October 2007. Peripheral blood
samples were prospectively collected prior to and at various time
points after HSCT. Tregs were defined by their immunophenotype
(CD31CD41CD25highCD127dim) and are expressed as a percentage
of total CD41 T-cells. FoxP3 and CTLA4 mRNA expression was
performed in duplicate with 500ng mRNA in a LightCycler with
TaqMan probes, and is presented in arbitrary units as a normalized
ratio to the level of expression of b2-microglobulin. Immune recon-
stitution of Tregs occurs unexpectedly early after HSCT. The per-
centage of Tregs triples the pretransplant baseline level at only
two weeks postransplant (6.35% vs 2.17%; p\0.001; table 1). Tregs
remain high at day190 when lymphocyte count recovery starts tak-
ing place. The level of early Tregs expansion at day 114 showed
a strong correlation with the baseline Tregs level prior to HSCT
(r 5 0.74; p 5 0.029). Markers of Tregs regulatory function such
as FoxP3 (10.32 vs 3.0; p 5 0.003) or CTLA4 (13.21 vs 6.35; p 5
0.082) outline a profile of mRNA expression that mirrors the early
expansion of Tregs, providing additional evidence of a true func-
tional immune reconstitution of Tregs early after SCT.
Table 1
Time CD31 Tregs FoxP3 CTLA4
Points Lymph (10e9/L) (% of CD41) (b2-ratio) (b2-ratio)Pre-HSCT 1.46 6 0.67 2.17 6 0.96 3.00 6 4.78 6.35 6 6.64
Day 114 1.04 6 1.28 6.35 6 1.45 10.32 6 9.56 13.21 6 13.65
Day 190 2.07 6 1.15 5.87 6 2.13 2.42 6 1.85 6.22 6 4.49
ANOVA 0.061 0.001 0.003 0.082values in table are mean6S.D.This is the first study to analyze the kynetics of immune recovery
of Tregs after autologous HSCT, and it shows that it takes place as
early as two weeks into the procedure. Although FoxP3 and CD25-
expression can be induced in non-regulatory T-cells by early allor-
reactive phenomena after allogeneic SCT, this should not be a con-
founding factor or compromise the analysis in the autologous
setting. Understanding the early kynetics of Tregs postransplant re-
constitution offers potential targets for immunomodulatory thera-
peutic strategies at the early phase of Tregs expansion
postransplant or even at their baseline level which correlates with
their subsequent expansion.391
DIFFERENTIAL GENOMIC EXPRESSION OF NK RECEPTOR (NKR) IN CORD
BLOOD (CB) CD56DIM VERSUS PERIPHERAL BLOOD (PB) CD56DIM NK
CELLS: IMPLICATION FOR IMMATURITY IN CORD BLOODNK CD56DIM IN-
NATE IMMUNITY
Shereck, E.1, Day, N.S.1, Ayello, J.1, McGuinn, C.1, Satwani, P.1,
Lewis, D.1, van de Ven, C.1, Wapner, R.J.2, Lim, M.3, Cairo, M.S.1,4,5
1 Morgan Stanley Children’s Hospital New York Presbyterian, Columbia
University, New York, NY; 2 New York Presbyterian Hospital, Columbia
University, New York, NY; 3 University of Michigan, Ann Arbor, MI;
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NK cells are characterized by absent CD3 but expression of
CD56dim (90%, cytotoxic) and CD56bright (10%, mediator). NK
cells may contribute to the immaturity in cord blood innate and
adaptive immunity, and play an important role in the GVL effect
post CBT.We previously demonstrated the ability to ex-vivo expand
CB into NK subsets with profoundNK in-vitro and in-vivo cytotoxic
activity (Ayello/Cairo BBMT 2006). We further observed differen-
tial protein profiling in CB vs PB CD56dim, in which NKG2A was
overexpressed (Shereck/Cairo, ASH 2007; ASPHO 2007; AACR
2007). The differential proteins also included IP3R type 3, NCR3,
MAPKAPK5, Notch 2, PLEK, and NF-X1. In this report, we com-
pared the genomic expression pattern in CB vs PBCD56dim. CB and
PB NK cells were isolated indirectly by magnetic separation from
non-NK cells. Then, the CD561 CD161 NK cells (CD56dim)
were selected with CD16 (FCGR3) MicroBeads. For genomic stud-
ies, total RNA was isolated and reverse transcribed to cDNA using
T7-Oligo (dT) primer. cRNA was Biotin-labeled by in vitro tran-
scription. Fragmented biotin-labeled cRNA was hybridized to Gen-
eChip U133A_2 (Affymetrix). Data were analyzed using Agilent
GeneSpring. Signal intensities were compared using one way AN-
OVA and Welch Test for statistical analysis. There were 193 and
222 genes over and under expressed at the genomic level between
CB vs PBCD56dimNK cells, respectively. CB vs PBCD56dim signif-
icantly overexpressed NKG2A (2.14F), CD16b (2.46F), KIR2D
(2.13F), NKp44 (NCR2; 2.62F), PBX1 (4.29F), ENPEP (3.93F).
There was no significant difference in NKR gene expression of
CD16a, CD161, NKG2C, and NKp46 in CB vs PB CD56dim. CB
vs PB CD56dim underexpressed IP3R (1.32F), MAPKAPK5
(1.77F), NCR3 (1.24F), ACACB (3.23F), BBS1 (2.00F). These re-
sults suggest that NKR protein product levels in CB CD56dim may
be directly regulated at the translation level. The differential gene ex-
pression of IP3R, ENPEP, PBX1, and MAPKAPK5 between CB vs
PB suggests the involvements of IP3 and calcium ions inNKR signal-
ing pathways. The potential regulators of this process may include
PBX1, ENPEP, ACACB, and BBS1.We conclude that genomic dif-
ferences between CB vs PB CD56dim may play an important role in
regulating NKR signaling pathway, and thus contribute to disparate
cytotoxic activity between CB vs PB and suggest a possible explana-
tion for immaturity of cord blood innate and adaptive immunity.
(The first two authors contributed equally.)392
HUMAN HERPES VIRUS TYPE 6 REACTIVATION AFTER HAEMATOPOIETIC
STEM CELL TRANSPLANTATION: SUPERIOR SPECIFIC HHV6 T-CELL RE-
SPONSES ARE ASSOCIATED WITH POOR CLINICAL OUTCOME
de Pagter, A.P.J.1, Boelens, J.J.1, Tesselaar, K.3, Nanlohy, N.3,
Bloem, A.3, Schuurman, R.2, van Baarle, D.3 1 University Medical
